Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization

Hdl Handle:
http://hdl.handle.net/10675.2/787
Title:
Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization
Authors:
Awan, Farrukh T.; Kochuparambil, S. Thomas; DeRemer, David; Cumpston, Aaron; Craig, Michael; Jillella, Anand; Hamadani, Mehdi ( 0000-0001-5372-510X )
Abstract:
The combination of filgrastim (G-CSF) and plerixafor is currently approved for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin lymphoma and multiple myeloma undergoing autologous peripheral blood hematopoietic cell transplantation. However, chemotherapy and G-CSF-based mobilization remains a widely used strategy for peripheral blood progenitor cell collection. In this paper we describe our experience from two North American transplant centers in a series of patients who received salvage plerixafor while failing chemotherapy and G-CSF mobilization. Patients received a median of two doses of plerixafor salvage upon failure to mobilize adequate number of peripheral blood progenitor cells at neutrophil recovery. The use of plerixafor was associated with a 2.4-fold increase in peripheral blood CD34+ cell count and 3.9-fold increase in total CD34+ cell yield. All patients were able to collect â ¥2 Ã 106 CD34+â cells/kg with this approach. These results were more pronounced in patients with a higher CD34+ cell count at the time of the first plerixafor dose. Interestingly, peripheral blood white blood cell count was not shown to correlate with a response to plerixafor. Our results provide safety and efficacy data for the use of plerixafor in patients who are destined to fail chemomobilization.
Citation:
J Oncol. 2012 Apr 10; 2012:931071
Issue Date:
10-Apr-2012
URI:
http://hdl.handle.net/10675.2/787
DOI:
10.1155/2012/931071
PubMed ID:
22570654
PubMed Central ID:
PMC3335320
Type:
Article
ISSN:
1687-8469
Appears in Collections:
Department of Medicine Faculty: Research and Presentations

Full metadata record

DC FieldValue Language
dc.contributor.authorAwan, Farrukh T.en_US
dc.contributor.authorKochuparambil, S. Thomasen_US
dc.contributor.authorDeRemer, Daviden_US
dc.contributor.authorCumpston, Aaronen_US
dc.contributor.authorCraig, Michaelen_US
dc.contributor.authorJillella, Ananden_US
dc.contributor.authorHamadani, Mehdien_US
dc.date.accessioned2012-10-26T20:30:44Z-
dc.date.available2012-10-26T20:30:44Z-
dc.date.issued2012-04-10en_US
dc.identifier.citationJ Oncol. 2012 Apr 10; 2012:931071en_US
dc.identifier.issn1687-8469en_US
dc.identifier.pmid22570654en_US
dc.identifier.doi10.1155/2012/931071en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/787-
dc.description.abstractThe combination of filgrastim (G-CSF) and plerixafor is currently approved for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin lymphoma and multiple myeloma undergoing autologous peripheral blood hematopoietic cell transplantation. However, chemotherapy and G-CSF-based mobilization remains a widely used strategy for peripheral blood progenitor cell collection. In this paper we describe our experience from two North American transplant centers in a series of patients who received salvage plerixafor while failing chemotherapy and G-CSF mobilization. Patients received a median of two doses of plerixafor salvage upon failure to mobilize adequate number of peripheral blood progenitor cells at neutrophil recovery. The use of plerixafor was associated with a 2.4-fold increase in peripheral blood CD34+ cell count and 3.9-fold increase in total CD34+ cell yield. All patients were able to collect â ¥2 Ã 106 CD34+â cells/kg with this approach. These results were more pronounced in patients with a higher CD34+ cell count at the time of the first plerixafor dose. Interestingly, peripheral blood white blood cell count was not shown to correlate with a response to plerixafor. Our results provide safety and efficacy data for the use of plerixafor in patients who are destined to fail chemomobilization.en_US
dc.rightsCopyright © 2012 Farrukh T. Awan et al.en_US
dc.subjectResearch Articleen_US
dc.titlePlerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilizationen_US
dc.typeArticleen_US
dc.identifier.pmcidPMC3335320en_US
dc.contributor.corporatenameDepartment of Medicine-
dc.contributor.corporatenameDepartment of Pharmacology and Toxicology-
All Items in Scholarly Commons are protected by copyright, with all rights reserved, unless otherwise indicated.